PsyNews.com

This morning, LSD drug developer Definium Therapeutics shared positive topline data from its second Phase 3 study of its lead candidate, DT120, in generalised...

Join us after the FDA’s September 14 psychedelics hearing for THE GATEWAY—an evening of networking, conversation, and a live podcast recording about what happened...

Post Content

In a commentary published in the New England Journal of Medicine yesterday, FDA outlined what it describes as its “new framework for psychedelic drugs”....

  Thanks to Chronicle of Philanthropy for this: For decades, philanthropy played an unusually important role in keeping psychedelic science alive when governments, major foundations and...

Post Content

As potential approvals of psychedelic therapies draw closer, attention is increasingly turning to what their real-world delivery might look like. While many details remain...

Devon Phillips, partnerships manager at MAPS, argues that people rarely change because they got better information. They change when it arrives through someone they...

Large pharmaceutical companies appear to be ramping up U.S. Google ad spend targeting psychedelics-related keywords, with the most common ads pointing to Johnson &...

Earlier this month, we covered Definium Therapeutics’ second Phase 3 readout, this time pertaining to its first LSD (DT120) for generalised anxiety disorder (GAD)...

A donor gift with no diagnosis requirement forced a debate inside Thank You Life. Its executive director asks whether documented suffering should remain the...

Oregon's psilocybin program posted its first real-world outcome data this week, just as regulators move on fee increases that operators say could close the...